HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G. by Palma, A.C. et al.
HIV-1 protease mutation 82M contributes to phenotypic resistance
to protease inhibitors in subtype G
Ana Carolina Palma1,2*, Kris Covens1,3,4, Joke Snoeck1,5, Anne-Mieke Vandamme1,6, Ricardo Jorge Camacho2,6
and Kristel Van Laethem1,7
1Clinical and Epidemiological Virology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium; 2Laborato´rio
de Biologia Molecular, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal; 3PharmAbs, The KULeuven Antibody
Centre, Leuven, Belgium; 4Center for Molecular and Vascular Biology, Leuven, Belgium; 5IMUL-CHUV, Institute of Microbiology, Lausanne,
Switzerland; 6Centro de Mala´ria e outras Doenc¸as Tropicais, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa,
Lisboa, Portugal; 7AIDS Reference Laboratory, University Hospitals Leuven, Leuven, Belgium
*Corresponding author. Tel: +32-16-332178; Fax: +32-16-332131; E-mail: acmpalma@gmail.com
Received 27 September 2011; returned 15 November 2011; revised 9 January 2012; accepted 10 January 2012
Objectives: The purpose of this study was the qualitative and quantitative assessment of the in vitro effect of
HIV-1 protease (PR) mutation 82M on replication capacity and susceptibility to the eight clinically available PR
inhibitors (PIs).
Methods: The 82M substitution was introduced by site-directed mutagenesis in wild-type subtype B and G
strains, as well as reverted back to wild-type in a therapy-failing strain. The recombinant viruses were evaluated
for their replication capacity and susceptibility to PIs.
Results: The single 82M mutation within a wild-type subtype B or G background did not result in drug resist-
ance. However, the in vitro effect of single PR mutations on PI susceptibility is not always distinguishable
from wild-type virus, and particular background mutations and polymorphisms are required to detect signifi-
cant differences in the drug susceptibility profile. Consequently, reverting the 82M mutation back to wild-
type (82I) in a subtype G isolate from a patient that failed therapy with multiple other PR mutations did
result in significant increases in susceptibility towards indinavir and lopinavir and minor increases in suscepti-
bility towards amprenavir and atazanavir. The presence of the 82M mutation also slightly decreased viral rep-
lication, whether it was in the genetic background of subtype B or subtype G.
Conclusions: Our results suggest that 82M has an impact on PI susceptibility and that this effect is not due to a
compensatory effect on the replication capacity. Because 82M is not observed as a polymorphism in
any subtype, these observations support the inclusion of 82M in drug resistance interpretation systems and
PI mutation lists.
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Introduction
The rise of HIV-1 non-B subtypes in Europe and the roll-out of
antiviral therapy in the developing world have led to the initiation
of studies investigating the impact of HIV-1 genetic variability
on in vitro and in vivo drug susceptibility. Although certain
polymorphisms were associated with slightly increased and/or
decreased in vitro drug susceptibility,1 several observational
studies revealed that HIV-1 patients were as likely to achieve
first-line therapy success irrespective of their subtype.2
However, other studies illustrated the emergence of subtype-
specific drug resistance mutations, underscoring the limitations
of genotypic drug resistance interpretation systems that failed
to include these novel mutations.3
A previous study revealed that the novel 82M protease (PR)
substitution was significantly linked to subtype G and to indinavir
and lopinavir exposure. The aim of this study was to explore its
role in HIV-1 subtype G susceptibility towards PR inhibitors (PIs).4
Materials and methods
Viral RNAwas extracted from plasma samples obtained from HIV-1 subtype
G patients. For subtype B, the p83.2 vector was obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH. The
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PR sequences were amplified, cloned and sequenced as previously
described.5 Mutations at PR position 82 were introduced by site-directed
mutagenesis. The drug susceptibility and replication capacity of the recom-
binant viruses were assessed as previously described.5 Statistical analysis
was performed in Microsoft Excel using a two-sided Student’s t-test and
the Bonferroni correction to account for multiple analyses.
Results and discussion
The historical connection between Portugal and some African
countries has produced an HIV-1 epidemiological profile that is
dominated by subtypes B (41.7%) and G (29.4%). A study that
aimed at detecting subtype-specific drug resistance mutations
within PR showed differences in the prevalence of amino acids
at PR position 82 between naive and treated patients within
each subtype (Table 1). Correction for the difference in PI expos-
ure and the inherent amino acid differences between the two
subtypes revealed that within the Portuguese dataset the PR
82M substitution was 27 times more likely to occur in subtype
G than in subtype B, and that the presence of that particular
amino acid substitution was significantly associated with experi-
ence of indinavir and/or lopinavir/ritonavir.4 As early as 1 year
after their respective clinical approval, amino acid substitutions
at PR position 82 were associated with reduced susceptibility
to both drugs.6,7 Resistance development to indinavir occurred
through variable patterns of several substitutions, but all resist-
ant isolates displayed 46I/L and/or 82A/F/T.6 The latter muta-
tions were also significantly associated with reduced in vitro
susceptibility to lopinavir.7 The purpose of this study was to
assess qualitatively and quantitatively the in vitro effect of 82M
on replication capacity and susceptibility to the available PIs.
A subtype B and a subtype G strain that could be considered
as representative for both subtypes were selected from our re-
pository of reference viruses and clinical isolates (Table 2). The
82M substitution was introduced by site-directed mutagenesis
in both backgrounds, whereas the 82A and 82F mutations
were elected to be introduced in the subtype B background,
because 82A is the most prevalent amino acid change after in
vivo PI exposure in subtype B and 82F is reported with the
highest fold-change in susceptibility towards indinavir (1–3-
fold).8 The recombinant viruses were tested phenotypically, but
no significant effect against indinavir and lopinavir was detected,
either for subtype B or for subtype G (Table 2). This was not en-
tirely unexpected, since, in contrast to non-nucleoside reverse
transcriptase inhibitor (NNRTI) resistance, the in vitro effect of
single PR mutations on PI susceptibility is not always distinguish-
able from wild-type virus and not even by standard commercially
available assays.8 Often, particular background mutations and
polymorphisms are required to detect significant differences in
the drug susceptibility profile. Therefore, the next step in our
study was to analyse the effect of the 82M mutation in the
presence of major PI mutations.
For that purpose, a sample from a patient who was infected
with a subtype G virus and failing PI therapy in the presence of
82M was selected (GMT). Although 82M has also been observed
in subtype B isolates,9 none of the subtype B patients attending
the University Hospitals Leuven and only one patient at the
Laborato´rio de Biologia Molecular (Lisbon) displayed this muta-
tion. Unfortunately, no patient sample was available for further
analysis.
Drug susceptibility testing revealed that GMT was highly resist-
ant to both indinavir (31-fold) and lopinavir (97-fold) (Table 2).
Table 1. Prevalence of amino acid changes at PR position 82 in PI-naive and PI-treated patients
PR mutationa
Subtype B Subtype G
PI naive PI treated PI naive PI treated
HIVdbb Portugalc HIVdbb Portugalc HIVdbb Portugalc HIVdbb Portugalc
82V 98.3% 97.7% 39.1% 56% 10% 2% 6.4% 5.7%
82I 1.7% 2.3% 1.6% 1.6% 90% 98% 72% 67%
82A ,0.0% — 29% 33% — — 3.3% 3.3%
82T — — 3.6% 4.5% — — 10% 11%
82F — — 2.1% 3.2% — — 1.7% 1.9%
82S ,0.0% — 1.5% 0.5% — — 3.3% 3.3%
82C — — 0.9% 0.5% — — — —
82L — — 0.3% — — — — —
82M — — 0.1% 0.2% — — 3.3% 7.7%
82H — — ,0.0% — — — — —
82R — — ,0.0% — — — — —
82L ,0.0% — — — — — — —
aPR polymorphisms within wild-type subtype B and G strains (82V and 82I, respectively) and PR mutations within PI-treated subtype B and G strains,
ordered according to prevalence within subtype B.
bAt the time of analysis, 13910 PI-naive subtype B, 7074 PI-treated subtype B, 829 PI-naive subtype G and 247 PI-experienced subtype G strains were
available within the HIV drug resistance database.8
cAt the time of analysis, 133 PI-naive subtype B, 440 PI-treated subtype B, 151 PI-naive subtype G and 209 PI-experienced subtype G strains were
available within the Portuguese database.
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Table 2. Genotypic and phenotypic characteristics of HIV-1 subtype B and G recombinant viruses
PR mutationsa
L10 I13 K14 I15 K20 E35 M36 R41 M46 I47 F53 I54 I62 L63 C67 H69 T74 V82 L89 L90
B — — — — — — — — — — — — — — — — — — — —
B-82M — — — — — — — — — — — — — — — — — M — —
B-82A — — — — — — — — — — — — — — — — — A — —
B-82F — — — — — — — — — — — — — — — — — F — —
GCON — V — — I — I K — — — — — — S K — I M —
G — V — — I — I K — — — — — P S K — I M —
G-82M — V — — I — I K — — — — — P S K — M M —
GMT V A R V I D I K I V L V V P Y K A M I M
GMT-82I V A R V I D I K I V L V V P Y K A I I M
Drug susceptibilityb Replication
capacityc
PI NRTI k R2
AMP ATV DRV IDV LPV NFV SQV TPV 3TC
B-82M — — — 1.1+0.5 1.0+0.6 — — — — 1.30 0.95
B-82A — — — 0.9+0.3 1.1+0.4 — — — — 1.35 0.99
B-82F — — — 0.7+0.2 0.7+0.3 — — — — 0.95 0.89
G-82M — — — 1.5+0.2 0.9+0.3 — — — — 1.01 0.97
GMT 17.3+3.5 13.4+3.3 3.3+1.0 30.7+12.7 96.6+17.3 18.9+7.5 4.6+1.0 4.3+1.0 1.1+0.3 1.45 0.99
GMT-82I 7.7+2.2 6.1+0.3 1.7+0.3 6.9+3.4 38.4+12.7 13.1+4.4 8.5+2.1 2.6+1.2 0.8+0.2 1.71 0.98
aPR mutations within the wild-type (B and G) and mutant viruses (B-82M, B-82A, B-82F, G-82M, GMT and GMT-82I), relative to the consensus sequence for subtype B, as obtained from
HIV databases (http://www.hiv.lanl.gov). For comparison, the consensus sequence for subtype G (GCON) is also displayed. Mutations in bold are the subject of the study. The frequencies
of the GMT background polymorphisms and mutations in other subtype G isolates containing the 82M mutation and present in the HIV drug resistance database are: 10V (38%), 13A
(38%), 14R (38%), 15V (50%), 20I (88%), 35D (75%), 36I (88%), 43K (75%), 46I (50%), 47V (0%), 53L (25%), 54V (88%), 62V (38%), 63P (50%), 67Y (0%), 69K (100%), 74A (0%), 89I
(75%) and 90M (63%).8
bDrug susceptibility of recombinant viruses towards PIs (AMP, amprenavir; ATV, atazanavir; DRV, darunavir; IDV, indinavir; LPV, lopinavir; NFV, nelfinavir; SQV, saquinavir; TPV, tipranavir)
and the NRTI lamivudine (3TC), expressed as mean fold-change and standard deviation. Values were obtained from at least three independent experiments, each performed in trip-
licate.5 A P value was calculated for the difference of fold-change between the site-directed mutant and the corresponding original virus strain (B-82M, B-82A, B-82F versus B, G-82M
versus G and GMT-82I versus GMT). Values with P,0.005 are displayed in bold.
cFor wild-type subtype B, k¼1.70 and R2¼0.99. For wild-type subtype G, k¼1.48 and R2¼0.98. The percentage of infected cells was measured every day and normalized to the per-
centage of infected cells at day 0 (day 0 is 72 h after initial infection, aim of 0.1% infected cells). The curves were fitted exponentially and the resulting k values (y¼ekt) were used as a
measure of replication capacity. Data are the means of at least three independent experiments, each performed in triplicate.5
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Reverting the 82M mutation back to 82I, the consensus wild-
type amino acid in subtype G, resulted in a significant increase
in susceptibility to both PIs (Table 2). Nevertheless, the recombin-
ant virus remained resistant to indinavir (7-fold) and lopinavir
(38-fold). Concurrently, the GMT and GMT-82I recombinant
viruses were studied for susceptibility to all other clinically avail-
able PIs, as particular amino acid changes at that position are
associated with in vitro cross-resistance to all PIs but saquina-
vir.10 The GMT recombinant displayed wild-type susceptibility
towards lamivudine and variable reductions in susceptibility
towards amprenavir (17-fold), atazanavir (13-fold), darunavir
(3-fold), nelfinavir (19-fold), saquinavir (5-fold) and tipranavir
(4-fold). Unlike for indinavir and lopinavir, the reversion of 82M
to 82I resulted in: (i) a,2-fold reduction in resistance levels, sug-
gesting a minor role for 82M in resistance towards amprenavir
and atazanavir; and (ii) no significant resistance reduction for
darunavir, nelfinavir and tipranavir. In accordance with a previ-
ously reported beneficial effect of some substitutions at the 82
position, namely 82F/L, on saquinavir susceptibility,10 we also
observed a slightly lower fold-change in resistance towards
saquinavir in GMT, when compared with GMT-82I.
Finally, a replication capacity assay was performed to assess
the qualitative nature of the impact of 82M on the virus’
fitness in the absence of drug (Table 2). In each of the three
independent experiments, the presence of the 82M mutation
slightly decreased the virus’ capacity to replicate, whether it
was present in the genetic background of wild-type subtype B,
wild-type subtype G or mutant subtype G; however, statistical
significance was not reached. This suggests that the higher
resistance level is not due to the compensatory role of 82M on
replication capacity, but has to be due to a direct effect on
drug activity, which could hypothetically be attributed to its
position within the active site of PR.
The propensity of subtype G to acquire the 82M mutation
more frequently than subtype B after PI exposure is likely due
to the differences in wild-type codon use at position 82 in PR.
For subtype B, the consensus is GTC, encoding for valine, and
for subtype G it is ATC, encoding for isoleucine (Table 1). This
makes the genetic barrier smaller in subtype G, as only one
mutation is required to achieve a methionine (ATC to ATG), in
contrast with the two mutations needed in subtype B (GTC to
ATG). This might also explain why the alanine substitution is 10
times less frequent in subtype G as opposed to in subtype B
(GTC to GCC), since it requires two mutations (ATC to GCC). The
codon ATC at PR position 82 is also the consensus in several
circulating recombinant forms containing subtype G within the
PR region (e.g. CRF06-cpx, CRF14_BG, CRF20_BG, CRF23_BG,
CRF24_BG, CRF25_cpx and CRF37_cpx) and it is also detected
in some strains from all other pure subtypes. This can explain, al-
though at a low frequency, the selection of 82M in PI-treated
patients infected with subtypes other than subtype G.9
Although our phenotypic assay is not clinically validated and
cut-offs cannot be extrapolated between different assays, it is
noteworthy that the here observed resistance levels for GMT
and GMT-82I were all well above the biological cut-offs of Virco-
TYPE HIV-1 and Phenosense.8 For the drugs for which clinical
cut-offs are available, GMT scored above the lower clinical
cut-off for saquinavir/ritonavir and tipranavir/ritonavir, and
above the upper clinical cut-off for amprenavir/ritonavir, indina-
vir/ritonavir and lopinavir/ritonavir. Reversion to 82I led to
potentially clinically relevant changes for amprenavir/ritonavir,
indinavir/ritonavir and lopinavir/ritonavir, as their fold-changes
dropped below their respective upper clinical cut-off values.
When the GMT sequence was interpreted using the genotypic
drug resistance interpretation systems in the HIV drug resistance
database (ANRS 2011.05, HIVdb v6.0.11 and Rega v8.0.2), all
drugs were scored resistant except for: (i) darunavir/ritonavir,
which received a susceptible score in ANRS and HIVdB and an
intermediate resistant score in Rega; and (ii) tipranavir/ritonavir,
which received an intermediate score in ANRS and HIVdb.
We noticed that 82M was not included in the ANRS system, but
was included in all but one PI rule in the HIVdb and
Rega systems. In both of the latter systems, the weight was the
highest for indinavir and lowest (zero) for darunavir. Nevertheless,
the reversion to 82I resulted in only a resistant-to-intermediate
change for atazanavir/ritonavir and lopinavir/ritonavir in HIVdb,
and for tipranavir/ritonavir in Rega.
In conclusion, the PR mutation 82M has been observed in clin-
ical practice for some time, but this is the first time that it has
been studied in vitro. We have shown that this mutation, when
present in a subtype G strain and within the background of
other PI mutations, significantly reduces the susceptibility
towards indinavir and lopinavir, and slightly towards other PIs.
According to our results, this effect on drug susceptibility is not
due to a compensatory effect on the replication capacity.
Because 82M is not observed as a polymorphism in any
subtype, these observations support the inclusion of 82M in
drug resistance interpretation systems and PI mutation lists.
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